John Langowski
About John Langowski
John Langowski serves as the Vice President of Cell Therapy Research and Emeryville Site Head at Kite Pharma, bringing extensive experience in advancing clinical trials in various treatment modalities. He has a strong academic background in immunology and molecular biology, complemented by significant roles at several leading biopharmaceutical companies.
Current Role at Kite Pharma
John Langowski serves as the Vice President of Cell Therapy Research and the Emeryville Site Head at Kite Pharma. He has held this position since 2021, overseeing the advancement of cell therapy initiatives. His leadership focuses on enhancing research efforts and ensuring alignment with clinical trial objectives.
Previous Experience at Kite Pharma
Langowski has held multiple roles at Kite Pharma prior to his current position. He served as Executive Director of Cell Biology from 2019 to 2021 and as Senior Director of Cell Biology from 2018 to 2019. In these roles, he contributed to the development and implementation of cell therapy research strategies.
Education and Expertise
Langowski has a solid educational foundation in the life sciences. He earned a Bachelor of Science in Molecular Biology from The University of Texas at Austin. He furthered his studies at The University of Texas Graduate School of Biomedical Sciences at Houston, where he obtained both a Master of Science and a Doctor of Philosophy in Immunology.
Career Background in Biopharma
Langowski has extensive experience in the biopharmaceutical industry. He worked at Schering-Plough Biopharma as a Postdoctoral Fellow from 2003 to 2006 and held various positions at Nektar Therapeutics, including Senior Scientist and Associate Director in Research Biology. He also served as a Research Investigator at Novartis Institutes for BioMedical Research from 2007 to 2014.
Research Contributions and Leadership
Langowski has demonstrated strategic leadership in advancing cell therapy research. His background in immunology, oncology, and inflammation supports his role in driving programs from development to clinical trials. He is recognized for fostering cross-functional team engagement and achieving program milestones.